Biocon’s moment of reckoning
With biosimilars in the limelight, Kiran Mazumdar-Shaw’s company is poised to become one of India’s most important drug makers
21 April, 2020•12 min
0
21 April, 2020•12 min
0
More in Business
Business
India Inc. has an emissions blind spot
Indian companies risk losing out in global competitiveness as pricing power shifts toward those with verifiable emissions reporting.
You may also like
Internet
In India’s Lenskart IPO, a success for ADIA
The sovereign wealth fund’s big bet on the Indian eyewear company, Microsoft’s AI win in the Emirates and other updates from the week.
Internet
Takeaways from Dubizzle’s rare pause on IPO
The classifieds company postponed its influential public listing on the Dubai stock exchange. A mismatch of expectations was at the core of it.
Business
Can Meesho’s value-commerce playbook pass the IPO test?
The ecommerce platform will be hard-pressed to justify its estimated $7-8 billion valuation—up nearly 2x from just 10 months ago—at a time of ho-hum growth and flagging profitability.
